Table 3 Comparison of our meta-analysis with another published meta-analysis
Mou‐Bo Si 2019 [16] | Xiaocheng Li 2019 [20] | Shan Jin 2020 [17] | Zhijun Li 2021 [19] | Our study | |
|---|---|---|---|---|---|
Total studies included in MA | 6 | 10 | 7 | 19 | 19 |
Total sample size | 597 | 1570 | 615 | 2038 | 3756 |
Language of included studies | English | English | English | 3 in English,16 in Chinese | English |
Number of outcomes analyzed | 6 | 4 | 5 | 9 | 16 |
Subgroup analysis based on | Tumor size and RFA approaches | Tumor sizes | NR | Tumor sizes, RFA approaches and study areas in China | RFA approaches |
Meta regression covariates | NR | NR | NR | NR | age, tumor size, total bilirubin, and alpha-fetoprotein |
OS, DFS, RFS measured at | At 1 year, and 3 years | At 1year,3 years, and 5 years | NR | At 1 year, and 3 years | At 1year,3 years, and 5 years |
Overall survival | At 1year no statistical differences At 3 years favors MIS group | Favors LH at 1year,3 years, and 5 years | NR | At 1year no statistical differences At 3 years favors LLR group | Favors LLR group at 1year,3 years, and 5 years |
Overall survival PSM | NR | NR | NR | NR | At 3 years Favors LLR group, At 1and 5 years no statistical differences |
Disease‐free survival | At 1 year and 3 years favors MIS group | At 1 year and 3 years favors LH At 5 years no statistical differences | NR | At 1 year and 3 years favors LLR group | At 1 year and 3 years favors LLR group, at 5 years no statistical differences |
Disease‐free survival PSM | NR | NR | NR | NR | At 1 year and 3 years favors LLR group, at 5 years no statistical differences |
Recurrence-free survival | NR | NR | NR | NR | Favors LLR group |
Recurrence-free survival PSM | NR | NR | NR | NR | Favors LLR group |
Overall response rate | NR | NR | NR | Favors RFA group | NR |
Local recurrence | Higher with RFA group | Higher with RFA group | Higher with RFA group | Higher with RFA group | Higher with RFA group |
Intrahepatic recurrence | NR | NR | NR | NR | Higher with RFA group |
Extrahepatic recurrence | NR | NR | NR | NR | no statistical differences |
Postoperative liver function index | NR | NR | NR | RFA group had lower AST and higher ALB levels, with no significant differences in ALT, TBIL, and AFP levels | NR |
Duration of surgery | Lower with RFA group | NR | Lower with RFA group | Lower with RFA group | Lower with RFA group |
Duration of hospital stay | Lower with RFA group | NR | Lower with RFA group | NR | Lower with RFA group |
Incidence of blood transfusion during surgery | NR | NR | Lower with RFA group | Lower with RFA group | Lower with RFA group |
Estimated bleeding volume during surgery | NR | NR | Lower with RFA group | Lower with RFA group | NR |
All complications | Higher with MIS | Higher with LH group | NR | Higher with LLR group | Higher with LLR group |
30-days mortality | NR | NR | NR | NR | lower with LLR group |
90-days mortality | NR | NR | NR | NR | Higher with LLR group |
Major complications | NR | NR | NR | NR | Higher with LLR group |